Five genes exhibited HRs greater than 1.3 (30% increase in hazard for one standard deviation unit (Zscore) increase in mRNA expression): ENO1, GLRX2, PLOD1, PRDX4, TMED9, and TAGLN2 showed an HR of 1.7, controlling for TGFB2 mRNA expression, chemotherapy treatment, age at diagnosis, and subtypes of breast cancer (Figure 7, Table 1). This evidence concerns the gene TGFB2 and breast carcinoma.